SG11201707904XA - Recombinant mumps virus jeryl lynn 2 based vaccine - Google Patents

Recombinant mumps virus jeryl lynn 2 based vaccine

Info

Publication number
SG11201707904XA
SG11201707904XA SG11201707904XA SG11201707904XA SG11201707904XA SG 11201707904X A SG11201707904X A SG 11201707904XA SG 11201707904X A SG11201707904X A SG 11201707904XA SG 11201707904X A SG11201707904X A SG 11201707904XA SG 11201707904X A SG11201707904X A SG 11201707904XA
Authority
SG
Singapore
Prior art keywords
mumps virus
based vaccine
jeryl lynn
recombinant mumps
virus jeryl
Prior art date
Application number
SG11201707904XA
Other languages
English (en)
Inventor
Reinhard Glueck
Viviana Giannino
Gaurav Gupta
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of SG11201707904XA publication Critical patent/SG11201707904XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18751Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18761Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG11201707904XA 2015-03-27 2016-03-28 Recombinant mumps virus jeryl lynn 2 based vaccine SG11201707904XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1055MU2015 2015-03-27
PCT/IN2016/000074 WO2016157208A1 (en) 2015-03-27 2016-03-28 Recombinant mumps virus jeryl lynn 2 based vaccine

Publications (1)

Publication Number Publication Date
SG11201707904XA true SG11201707904XA (en) 2017-10-30

Family

ID=55948921

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201707904XA SG11201707904XA (en) 2015-03-27 2016-03-28 Recombinant mumps virus jeryl lynn 2 based vaccine

Country Status (21)

Country Link
EP (1) EP3274447B1 (hu)
JP (2) JP2018510642A (hu)
KR (1) KR101970428B1 (hu)
CN (1) CN107667175A (hu)
AR (1) AR104271A1 (hu)
AU (1) AU2016242460B2 (hu)
BR (1) BR112017020643A2 (hu)
CA (1) CA2980847C (hu)
DK (1) DK3274447T3 (hu)
ES (1) ES2764677T3 (hu)
HR (1) HRP20200018T1 (hu)
HU (1) HUE047571T2 (hu)
IL (1) IL254698A0 (hu)
LT (1) LT3274447T (hu)
MX (1) MX2017012389A (hu)
PL (1) PL3274447T3 (hu)
PT (1) PT3274447T (hu)
RS (1) RS59774B1 (hu)
SG (1) SG11201707904XA (hu)
SI (1) SI3274447T1 (hu)
WO (1) WO2016157208A1 (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107233576B (zh) * 2017-08-08 2020-02-07 江苏省农业科学院 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用
CN111218473A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种拯救腮腺炎病毒的系统和方法
CN109593784A (zh) * 2019-01-14 2019-04-09 浙江大学 一种用于拯救腮腺炎病毒的系统及拯救方法
CN109628414B (zh) * 2019-01-14 2021-03-30 浙江大学 一种mRNA甲基转移酶缺陷型腮腺炎病毒及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014083A1 (en) * 1993-11-19 1995-05-26 Smithkline Beecham Biologicals (S.A.) Vaccine against mumps containing a jeryl-lynn virus strain
EP1090108B1 (en) * 1998-06-03 2011-02-23 Wyeth Holdings Corporation Novel methods for rescue of rna viruses
AU6514900A (en) * 1999-08-02 2001-02-19 Wyeth Rescue of mumps virus from cdna
MXPA05013141A (es) * 2003-06-09 2006-03-17 Wyeth Corp Metodo mejorado para la recuperacion de arn virus de cadena negativa, no segmentados, a partir de adnc.
AU2006315026B2 (en) * 2005-11-21 2012-11-22 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
AU2010277310B2 (en) * 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems

Also Published As

Publication number Publication date
SI3274447T1 (sl) 2020-03-31
IL254698A0 (en) 2017-11-30
CN107667175A (zh) 2018-02-06
BR112017020643A2 (pt) 2018-07-17
EP3274447B1 (en) 2019-10-16
PL3274447T3 (pl) 2021-07-19
WO2016157208A9 (en) 2017-03-16
AU2016242460B2 (en) 2019-04-18
JP2020074792A (ja) 2020-05-21
LT3274447T (lt) 2020-02-10
RS59774B1 (sr) 2020-02-28
WO2016157208A1 (en) 2016-10-06
PT3274447T (pt) 2020-01-21
MX2017012389A (es) 2018-09-19
HUE047571T2 (hu) 2020-04-28
DK3274447T3 (da) 2020-01-27
JP2018510642A (ja) 2018-04-19
CA2980847A1 (en) 2016-10-06
ES2764677T3 (es) 2020-06-04
AR104271A1 (es) 2017-07-12
AU2016242460A1 (en) 2017-10-19
CA2980847C (en) 2020-03-24
KR101970428B1 (ko) 2019-04-18
KR20170131659A (ko) 2017-11-29
HRP20200018T1 (hr) 2020-03-20
EP3274447A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
HK1255847A1 (zh) 針對乙型肝炎病毒的疫苗
ZA201804071B (en) Recombinant zika vaccines
ZA201801035B (en) Vaccine compositions
PL3718565T3 (pl) Szczepionki przeciwko wirusom układu oddechowego
SG10201913630YA (en) Zika virus vaccine
LT3393510T (lt) Zikos viruso vakcina
HK1250136A1 (zh) 具有改善的穩定性和免疫原性之疫苗組合物
GB201613191D0 (en) Zika virus vaccine
IL257025A (en) Recombinant orf virus vector
IL254698A0 (en) A vaccine based on the recombinant Jarl Lin mumps virus 2
GB201506041D0 (en) Avian vaccine
GB201504579D0 (en) Ovine vaccine
PT3393510T (pt) Vacina contra o vírus zika
GB201702193D0 (en) Hepatitis E virus vaccine
GB201521608D0 (en) Vaccine composition